A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course

References

• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel of the European LeukemiaNet. Blood 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Macintyre EA, Gabert J, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901–1928.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000;96:1297–1308.
   PubMed Web of Science ®Google Scholar
• Jansen JH, De Ridder MC, Geertsma WMC, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1999;94:39–45.
   PubMed Web of Science ®Google Scholar
• Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoid acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997;17:109–113.
   PubMed Web of Science ®Google Scholar
• Arnould C, Philippe C, Bourdon V, Gregoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoid acid receptor α in acute promyelocytic leukemia. Hum Mol Genet 1999;8:1741–1749.
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911–1918.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434–2439.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Gari M, Goodeve A, Wilson G, et al. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894–900.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PL, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielminelli P, Poli G, et al. Influence of JAK2 V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41–48.
   PubMed Web of Science ®Google Scholar
• Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009;145:24–33.
   PubMed Web of Science ®Google Scholar
• Najfeld V, Chen A, Scalise A, Ambinder EP, Fernandez G, Waxman S. Myelodysplastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. Genes Chromosomes Cancer 1994;10:15–25.
   PubMed Web of Science ®Google Scholar
• Nakata Y, Mori T, Yamazaki T, et al. Acute myeloid leukemia with hypergranular cytoplasm accompanied by t(X;11)(q24;q23) and rearrangement of the MLL gene. Leuk Res 1999;23:85–88.
   PubMed Web of Science ®Google Scholar
• Slater RM, Von Drunen E, Kroes WG, et al. t(7;12)(q36;p13)- and t(7;12)(q32;p13)-translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001;15:915–920.
   PubMed Web of Science ®Google Scholar
• Sucic M, Zadro R, Burazer B, et al. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. J Hematother Stem Cell Res 2002;11:941–950.
   PubMedGoogle Scholar
• Zhang L, Mulvihill JJ, Kern WF, McMinn J, Li S. Duplication 15q as the sole anomaly in an acute promyelocytic leukemia patient without t(15;17). Cancer Genet Cytogenet 2002;138:17–21.
   PubMed Web of Science ®Google Scholar
• Frater JL, Hoover RG, Bernreuter K, Batanian JR. Deletion of MYC and presence of double minutes with MYC amplification in a morphologic acute promyelocytic leukemia-like case lacking RARA rearrangement: could early exclusion of double-minute chromosomes be a prognostic factor? Cancer Genet Cytogenet 2006;166:139–145.
   PubMed Web of Science ®Google Scholar
• Grimaldi B, Davis S, Zhang Y, et al. Double minutes identified as amplification of the MYC oncogene in AML with APL-like morphology without RARA rearrangement. Presented at Association of Genetic Technologists 32nd Annual Meeting, Denver, CO, 31May–3June2007;69: Abstract266 9.
   Google Scholar
• Kamath A, Tara H, Xiang B, Bajaj R, He W, Li P. Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genet Cytogenet 2008;183:117–120.
   PubMed Web of Science ®Google Scholar
• Wang HP, Xu H, Chen ZM, Tong XM, Qian WB, Jin J. t(X;17) as the sole karyotypic anomaly in a case of M3r subtype of acute promyelocytic leukemia without RARα rearrangement. Leuk Res 2010;34:e55–e57.
   PubMed Web of Science ®Google Scholar
• Bruyere H, Sutherland H, Chipperfield K, Hudoba M. Concomitant and successive amplifications of MYC in APL-like leukemia. Cancer Genet Cytogenet 2010;197:75–80.
   PubMed Web of Science ®Google Scholar
• Song X, Gong S, Chen J, Gao L, Yang J, Wang J. ATRA is effective to an acute promyelocytic leukemia patient without RARA gene rearrangement. Leuk Res 2010;34:e190–e193.
   PubMed Web of Science ®Google Scholar
• Such E, Cervera J, Valencia A, et al. A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 2011;117:242–245.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006;108:2173–2181.
   PubMed Web of Science ®Google Scholar
• Scolnik MP, Palacios MF, Acevedo SH, et al. Promyelocytic blast crisis of chronic myelogenous leukaemia with translocations (9;22) and (15;17). Leuk Lymphoma 1998;31:231–236.
   PubMed Web of Science ®Google Scholar
• Sato N, Furukawa T, Masuko M, et al. Acute promyelocytic leukemia developing in untreated essential thrombocythemia. Am J Hematol 2002;71:114–116.
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375–379.
   PubMed Web of Science ®Google Scholar
• Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 1993;82:2967–2974.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndromes. J Clin Oncol 1993;11:1489–1495.
   PubMed Web of Science ®Google Scholar
• Ohno R, Naoe T, Hiraon M, et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993;81:1152–1154.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndrome with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266–1269.
   PubMed Web of Science ®Google Scholar
• Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101–109.
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002;99:1578–1584.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Ayari S, Vassilief D, et al. Is there a role for all-trans retinoic acid in combination with recombinant erythropoietin in myelodysplastic syndromes? A report on 59 cases. Leukemia 2009;23:673–678.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Ganser A, Seipelt G, et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999;78:125–130.
   PubMed Web of Science ®Google Scholar
• Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol 1996;72:237–244.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112–119.
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multileft study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006;24:2456–2464.
   PubMed Web of Science ®Google Scholar
• Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multileft study. J Clin Oncol 2006;24:2465–2471.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008;113:2504–2511.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res 2011;35:522–525.
   PubMed Web of Science ®Google Scholar